GRI Bio, Inc. - Common Stock (GRI)
1.8100
-0.2400 (-11.71%)
NASDAQ · Last Trade: Sep 14th, 6:53 PM EDT
Detailed Quote
Previous Close | 2.050 |
---|---|
Open | 2.060 |
Bid | 1.800 |
Ask | 1.830 |
Day's Range | 1.760 - 2.060 |
52 Week Range | 1.100 - 30.43 |
Volume | 1,010,923 |
Market Cap | 12.33M |
PE Ratio (TTM) | -0.0310 |
EPS (TTM) | -58.4 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 3,018,034 |
Chart
About GRI Bio, Inc. - Common Stock (GRI)
Gri Bio Inc is a biotechnology company focused on developing innovative therapies to enhance the immune response and improve the treatment of various diseases. The company leverages its proprietary technology platform to identify and create novel biopharmaceutical products aimed at addressing unmet medical needs in areas such as immunology and oncology. By harnessing the power of the immune system, Gri Bio strives to deliver breakthrough treatments that can significantly impact patient outcomes and contribute to advancements in modern medicine. Read More
News & Press Releases
Via Benzinga · September 12, 2025
Via Benzinga · September 12, 2025
Via Benzinga · September 11, 2025
Via Benzinga · September 11, 2025
Via Benzinga · July 31, 2025
Via Benzinga · July 22, 2025
- Video webcasts from participating companies now available here
Via ACCESS Newswire · July 22, 2025
GRI Bio reported interim Phase 2a results for GRI-0621 in IPF, showing safety and no significant cholesterol changes.
Via Benzinga · April 1, 2025

Via Benzinga · November 15, 2024

Via Benzinga · November 1, 2024

Via Benzinga · October 23, 2024

Via Benzinga · October 22, 2024

Via Benzinga · October 22, 2024

Via Benzinga · October 22, 2024

Via Benzinga · October 21, 2024

Via Benzinga · October 21, 2024

Via Benzinga · October 21, 2024

Via Benzinga · October 18, 2024

Via Benzinga · October 14, 2024

Via Benzinga · October 8, 2024